Nils Rudqvist
Overview
Explore the profile of Nils Rudqvist including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Larsson M, Rudqvist N, Spetz J, Shubbar E, Parris T, Langen B, et al.
PLoS One
. 2021 Oct;
16(10):e0259429.
PMID: 34705896
[This corrects the article DOI: 10.1371/journal.pone.0244098.].
2.
Larsson M, Rudqvist N, Spetz J, Shubbar E, Parris T, Langen B, et al.
PLoS One
. 2020 Dec;
15(12):e0244098.
PMID: 33382739
Background: Radioiodide (131I) is commonly used to treat thyroid cancer and hyperthyroidis.131I released during nuclear accidents, have resulted in increased incidence of thyroid cancer in children. Therefore, a better understanding...
3.
Ghandhi S, Sima C, Weber W, Melo D, Rudqvist N, Morton S, et al.
Radiat Res
. 2020 Sep;
196(5):478-490.
PMID: 32931585
Internal contamination by radionuclides may constitute a major source of exposure and biological damage after radiation accidents and potentially in a dirty bomb or improvised nuclear device scenario. We injected...
4.
Langen B, Rudqvist N, Spetz J, Helou K, Forssell-Aronsson E
PLoS One
. 2018 Jul;
13(7):e0197911.
PMID: 30001320
High-throughput gene expression analysis is increasingly used in radiation research for discovery of damage-related or absorbed dose-dependent biomarkers. In tissue samples, cell type-specific responses can be masked in expression data...
5.
Spetz J, Rudqvist N, Langen B, Parris T, Dalmo J, Schuler E, et al.
Nucl Med Biol
. 2018 Mar;
60:11-18.
PMID: 29502008
Introduction: Patients with neuroendocrine tumors expressing somatostatin receptors are often treated with Lu[Lu]-octreotate. Despite being highly effective in animal models, Lu[Lu]-octreotate-based therapies in the clinical setting can be optimized further....
6.
Rudqvist N, Laiakis E, Ghandhi S, Kumar S, Knotts J, Chowdhury M, et al.
Radiat Res
. 2018 Jan;
189(4):337-344.
PMID: 29351057
In the event of an improvised nuclear device or "dirty bomb" in a highly populated area, potentially hundreds of thousands of people will require screening to ensure that exposed individuals...
7.
Spetz J, Langen B, Rudqvist N, Parris T, Helou K, Nilsson O, et al.
BMC Cancer
. 2017 Aug;
17(1):528.
PMID: 28789624
Background: Lu-octreotate can be used to treat somatostatin receptor expressing neuroendocrine tumors. It is highly effective in animal models, but clinical studies have so far only demonstrated low cure rates....
8.
Rudqvist N, Spetz J, Schuler E, Parris T, Langen B, Helou K, et al.
PLoS One
. 2017 Feb;
12(2):e0171797.
PMID: 28222107
Humans are exposed to 131I in medical diagnostics and treatment but also from nuclear accidents, and better knowledge of the molecular response in thyroid is needed. The aim of the...
9.
Langen B, Rudqvist N, Spetz J, Swanpalmer J, Helou K, Forssell-Aronsson E
Sci Rep
. 2016 Oct;
6:30738.
PMID: 27779251
Non-targeted effects can induce responses in tissues that have not been exposed to ionizing radiation. Despite their relevance for risk assessment, few studies have investigated these effects in vivo. In...
10.
Langen B, Rudqvist N, Helou K, Forssell-Aronsson E
J Nucl Med
. 2016 Oct;
58(2):346-353.
PMID: 27765860
Methods: Expression microarray data from the kidney cortex and medulla, liver, lungs, and spleen were used from previous studies in which mice were intravenously injected with 0.064-42 kBq of At...